Predictive value of tumor mutational burden (TMB) in patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC) given first-line oxaliplatinbased chemotherapy and immune checkpoint blockade (ICB)

被引：0
|
作者：
Ree, Anne Hansen
Bousquet, Paula A.
Nilsen, Hilde L.
Luders, Torben
Wang, Shixiong
Visnovska, Tina
Bordin, Diana L.
Hoye, Eirik
Hamre, Hanne M.
Kersten, Christian
Hofsli, Eva
Guren, Marianne G.
Sorbye, Halfdan
Flatmark, Kjersti
Meltzer, Sebastian
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-2522
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2522
引用
收藏
页数：2
相关论文
共 33 条
  • [1] Tumor mutational burden (TMB) as a predictive biomarker of immune checkpoint blockade (ICB) in metastatic solid tumors
    Kao, Chester
    Powers, Eric
    Datto, Michael B.
    Green, Michelle
    Harrison, Michael Roger
    Armstrong, Andrew J.
    George, Daniel J.
    Clarke, Jeffrey Melson
    Strickler, John H.
    Zhang, Tian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [2] Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade
    Ree, Anne Hansen
    Hoye, Eirik
    Esbensen, Ying
    Beitnes, Ann-Christin R.
    Negard, Anne
    Bernklev, Linn
    Tetlie, Linn Kruse
    Fretland, Asmund A.
    Hamre, Hanne M.
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne G.
    Sorbye, Halfdan
    Nilsen, Hilde L.
    Flatmark, Kjersti
    Meltzer, Sebastian
    [J]. ONCOIMMUNOLOGY, 2024, 13 (01):
  • [3] First-line durvalumab plus monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC)
    Wainberg, Zev A.
    Diamond, Jennifer Robinson
    Curigliano, Giuseppe
    Deva, Sanjeev
    Bendell, Johanna C.
    Han, Sae-Won
    Kalyan, Aparna
    Naidoo, Jarushka
    Kim, Richard D.
    Patel, Sandip Pravin
    Kourtesis, Panagiotis
    Li, Xia
    Ascierto, Maria
    Song, Xuyang
    Das, Mayukh
    Segal, Neil Howard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [4] Systemic immune response invoked by short-course oxaliplatin-based chemotherapy (FLOX) for efficacy of sequential immune checkpoint blockade (ICB; nivolumab) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)
    Meltzer, Sebastian
    Flatmark, Kjersti
    Fuglestad, Anniken J.
    Hamre, Hanne M.
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne G.
    Sorbye, Halfdan
    Negard, Anne
    Ree, Anne Hansen
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [5] Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
    Meltzer, S.
    Berg, J. P.
    Hamre, H. M.
    Kersten, C.
    Hofsli, E.
    Guren, M. G.
    Sorbye, H.
    Flatmark, K.
    Ree, A. H.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S449 - S449
  • [6] A plasma-based analysis and genomic landscape of patients with high tumor mutational burden (TMB-H), microsatellite stable (MSS) colorectal cancer (CRC).
    Saeed, Anwaar
    Barnett, Reagan
    Lou, Emil
    da Silva, Luciana Madeira
    Cho, May Thet
    Lieu, Christopher Hanyoung
    Fakih, Marwan
    Kopetz, Scott
    Loree, Jonathan M.
    Gholami, Sepideh
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 249 - 249
  • [7] Immunogenic chemotherapy and immune checkpoint inhibition (ICI) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Biomarkers indicative of durable treatment response.
    Ree, Anne Hansen
    Meltzer, Sebastian
    Bakke, Kine M.
    Hamre, Hanne M.
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne Gronlie
    Sorbye, Halfdan
    Johansen, Christin
    Negard, Anne
    Redalen, Kathrine Roe
    Flatmark, Kjersti
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [8] First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial
    Ree, Anne Hansen
    Benth, Jurate Saltyte
    Hamre, Hanne M.
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne G.
    Sorbye, Halfdan
    Johansen, Christin
    Negard, Anne
    Bjornetro, Tonje
    Nilsen, Hilde L.
    Berg, Jens P.
    Flatmark, Kjersti
    Meltzer, Sebastian
    [J]. BRITISH JOURNAL OF CANCER, 2024, 130 (12) : 1921 - 1928
  • [9] Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma
    Andrews, Miles C.
    Li, Gerald
    Graf, Ryon P.
    Fisher, Virginia A.
    Mitchell, Jerry
    Aboosaiedi, Ali
    O'Rourke, Harriet
    Shackleton, Mark
    Iddawela, Mahesh
    Oxnard, Geoffrey R.
    Huang, Richard S. P.
    [J]. JCO PRECISION ONCOLOGY, 2024, 8
  • [10] Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma
    Andrews, Miles C.
    Li, Gerald
    Graf, Ryon P.
    Fisher, Virginia A.
    Mitchell, Jerry
    Aboosaiedi, Ali
    O'Rourke, Harriet
    Shackleton, Mark
    Iddawela, Mahesh
    Oxnard, Geoffrey R.
    Huang, Richard S. P.
    [J]. JCO PRECISION ONCOLOGY, 2024, 8
1234